Next user fee deal reveals where industry won at the negotiating table with FDA
Every five years, the way the FDA and the biopharma industry interact changes, sometimes more than a little bit. While the tried and true processes of drugmaker-FDA interactions remain intact, industry and the FDA spend months at the negotiating table hashing out new ways to alter their interactions and allow